NASHVILLE, Tenn., March 12,
2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:
CYRX) ("Cryoport" or "the Company"), a global leader in supply
chain solutions for the life sciences, today announced the launch
of MVE Biological Solutions' ("MVE") High-Efficiency 800 C, the
latest addition to its next-generation High-Efficiency ("HE")
Series of cryogenic freezers. The HE 800 C combines ergonomic
features and consistent performance in a compact size to meet the
evolving needs of fertility clinics, biorepositories and clinical
laboratories.
"With the HE 800 C, we are delivering an unmatched cryogenic
storage solution that balances high-capacity preservation with a
practical and user-friendly, space-efficient design," said
Jerrell Shelton, CEO, Cryoport.
"With the ability to store over 22,000 ½cc straws, the HE 800 C
offers ultra-cold, high-density storage while optimizing workflow,
enabling clinics and laboratories to maximize their available space
without compromising the security of these critical life sciences
materials."
Building on the trusted reputation of the HE Series, the HE 800
C provides ultra-low temperature storage at -190°C, ensuring the
integrity of sensitive biological materials. The HE 800 C is
compatible with SUC-1 inventory management systems, which enables
easy identification and retrieval of samples to streamline sample
organization and retrieval. Its superior ergonomic design makes
loading and retrieving samples more accessible, reducing strain on
laboratory personnel.
"Reliability, efficiency and access are key in cryogenic
storage, and the HE 800 C is designed to excel in these areas,"
added Mike Duich, President and CEO,
MVE Biological Solutions. "The HE 800 C provides enhanced sample
safety while making retrieval and organization more intuitive and
efficient, ultimately allowing medical researchers and clinicians
to focus on their work with confidence."
To learn more about the HE 800 C, please visit
https://mvebio.com/our-products/life-science-freezers/he800c or
reach out to marketing@mvebio.com.
About Cryoport, Inc.
Cryoport,
Inc. (Nasdaq: CYRX), is a
global leader in supply chain solutions for the Life Sciences with
an emphasis on cell & gene therapies. Cryoport
enables manufacturers, contract manufacturers
(CDMO's), contract research organizations
(CRO's), developers, and researchers to carry out
their respective business with products and services that are
designed to derisk services and provide certainty. We
provide a broad array of supply chain solutions for the life
sciences industry. Through our platform of critical products and
solutions including advanced temperature-controlled
packaging, informatics, specialized bio-logistics
services, bio-storage, bio-services, and cryogenic systems, we are
"Enabling the Future of Medicine™" worldwide, through our
innovative systems, compliant procedures, and agile approach to
superior supply chain management.
Our corporate headquarters, located in Nashville, Tennessee, is complemented by over
50 global locations in 17 countries, with key sites in the United States, United Kingdom, France, the
Netherlands, Belgium,
Portugal, Germany, Japan, Australia, India, and China.
For more information, visit www.cryoportinc.com or follow
via LinkedIn at
https://www.linkedin.com/company/cryoportinc or @cryoport on
X, formerly known as Twitter at www.twitter.com/cryoport for
live updates.
Forward-Looking Statements
Statements in
this press release which are not purely historical, including
statements regarding Cryoport's intentions, hopes,
beliefs, expectations, representations, projections, plans or
predictions of the future, are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited
to, those related to MVE Biological Solutions'
High-Efficiency 800 C freezer, including its potential impact on
revenue streams. It is important to note that
Cryoport's actual results could differ materially from those
in any such forward-looking statements. Factors that could cause
actual results to differ materially include, but are not limited
to, risks and uncertainties associated with the effect of changing
economic and geopolitical conditions, supply chain constraints,
inflationary pressures, the effects of foreign currency
fluctuations, trends in the products markets, variations in
Cryoport's cash flow, market acceptance risks, and technical
development risks. Cryoport's business could be
affected by other factors discussed in Cryoport's SEC
reports, including in the "Risk Factors" section of its most
recently filed periodic reports on Form 10-K and Form 10-Q, as well
as in its subsequent filings with the SEC. The forward-looking
statements contained in this press release speak only as of the
date hereof and Cryoport cautions investors not to
place undue reliance on these forward-looking statements. Except as
required by law, Cryoport disclaims any obligation,
and does not undertake to update or revise any forward-looking
statements in this press release.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryoports-mve-biological-solutions-expands-high-efficiency-cryogenic-freezer-series-with-answer-to-evolving-needs-of-fertility-clinics-biorepositories-and-clinical-laboratories-302399517.html
SOURCE Cryoport, Inc.
